Eton Pharmaceuticals, Inc.
StreetZero Signal 65
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. Founded in 2017 and headquartered in Deer Park, IL, it operates as a public company listed on NASDAQ under the ticker ETON. The company engages in pharmaceutical manufacturing and has completed multiple equity financings since its inception as a spin-out from Imprimis Pharmaceuticals.
LATEST FUNDINGRule 144
$5.3M
Announced 2026-11-10
TOTAL RAISED60.20M USD
IN THE NEWS
EMPLOYEES—
FOUNDED2017
HQDeer Park, IL, United States
Industry
Public Equity (NASDAQ)
Tags
PharmaceuticalsPublic CompanyPediatric DiseasesNASDAQ: ETON
Investors
Key highlights
- Completed $20M Series A financing in 2017 with healthcare investors.
- Raised approximately $22.5M through a 2020 public offering of common stock.
- Total funding across rounds reaches 60.20M USD.
- Operates as a NASDAQ-listed company with focus on rare pediatric treatments.
- Most recent noted round is Post-IPO Equity of 101K USD in 2025.
Ask StreetZero about Eton Pharmaceuticals, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account